{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:17:35Z","timestamp":1792664255245,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Toxic signaling of oligomeric protein species via binding to the cellular prion protein (PrP\n                    <jats:sup>C<\/jats:sup>\n                    ) is implicated in various neurodegenerative diseases, including Alzheimer\u2019s (AD) and Parkinson\u2019s disease (PD). Metabotropic glutamate receptor 5 (mGluR5) has been identified as a PrP\n                    <jats:sup>C<\/jats:sup>\n                    signaling partner, and pharmacological inhibition of mGluR5 was shown to improve cognitive performance and rescue long-term-potentiation (LTP) impairment in both in vitro and in vivo models of AD and PD. Prion diseases are another group of fatal neurodegenerative disorders that are characterized by templated misfolding of endogenous PrP\n                    <jats:sup>C<\/jats:sup>\n                    itself into the disease-driving counterpart PrP\n                    <jats:sup>Sc<\/jats:sup>\n                    . Besides its role in the self-propagating misfolding cascade and aggregation, PrP\n                    <jats:sup>Sc<\/jats:sup>\n                    also acts as a toxic PrP\n                    <jats:sup>C<\/jats:sup>\n                    ligand in aberrant signaling through mGluR5. Therefore, targeting metabotropic glutamate receptors has been proposed as a therapeutic strategy for the intervention of prion disease. In this study, we investigated the impact of long-term oral administration of two different selective mGluR5 inhibitors, the negative allosteric inhibitor CTEP and a\n                    <jats:italic>Silent Allosteric<\/jats:italic>\n                    mGluR5\n                    <jats:italic>Modulator<\/jats:italic>\n                    (SAM), in a mouse model of prion disease. Our findings demonstrate that treatment initiated during the preclinical phase significantly prolonged the survival of mice, whereas treatment starting after the onset of symptoms was no longer effective. Early treatment also delayed the formation of spongiosis, a pathological hallmark of prion diseases, but did not alter PrP\n                    <jats:sup>Res<\/jats:sup>\n                    levels. Preclinical dysregulation of mGluR5 could be shown in the mouse and a non-human primate model for prion diseases. Interestingly, in primary neurons, subacute treatment with CTEP blocked A\u03b2-induced, but not PrP\n                    <jats:sup>Sc<\/jats:sup>\n                    -associated synaptotoxicity. Thus, modes of action might differ markedly from those observed in models of Alzheimer\u2019s disease. Together, although our data show that targeting mGluR5 may be an efficient therapy, however, since treatment needs to be started early during prion disease progression, the narrow therapeutic window limits its therapeutic application in human prion diseases.\n                  <\/jats:p>","DOI":"10.1186\/s40478-026-02235-9","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T01:38:34Z","timestamp":1769650714000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Presymptomatic pharmacological inhibition of mGluR5 improves survival in a mouse model of prion diseases"],"prefix":"10.1186","volume":"14","author":[{"given":"Yue","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnam","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edda","family":"Thies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreu","family":"Matamoros-Angles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Tatzelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann C.","family":"Altmeppen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Sepulveda-Falla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Strittmatter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Glatzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Krasemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"2235_CR1","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.neuron.2009.12.016","volume":"64","author":"A Aguzzi","year":"2009","unstructured":"Aguzzi A, Rajendran L (2009) The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron 64:783\u2013790","journal-title":"Neuron"},{"key":"2235_CR2","doi-asserted-by":"publisher","first-page":"e1002579","DOI":"10.1371\/journal.pbio.1002579","volume":"14","author":"J Alibhai","year":"2016","unstructured":"Alibhai J, Blanco RA, Barria MA, Piccardo P, Caughey B, Perry VH, Freeman TC, Manson JC (2016) Distribution of misfolded prion protein seeding activity alone does not predict regions of neurodegeneration. PLoS Biol 14:e1002579. https:\/\/doi.org\/10.1371\/journal.pbio.1002579","journal-title":"PLoS Biol"},{"key":"2235_CR3","doi-asserted-by":"publisher","first-page":"8802","DOI":"10.1523\/JNEUROSCI.1224-16.2016","volume":"36","author":"CJ Ballester-Rosado","year":"2016","unstructured":"Ballester-Rosado CJ, Sun H, Huang JY, Lu HC (2016) mGluR5 exerts Cell-Autonomous influences on the functional and anatomical development of layer IV cortical neurons in the mouse primary somatosensory cortex. J Neurosci 36:8802\u20138814. https:\/\/doi.org\/10.1523\/JNEUROSCI.1224-16.2016","journal-title":"J Neurosci"},{"key":"2235_CR4","doi-asserted-by":"publisher","first-page":"21945","DOI":"10.1074\/jbc.M116.738286","volume":"291","author":"FH Beraldo","year":"2016","unstructured":"Beraldo FH, Ostapchenko VG, Caetano FA, Guimaraes AL, Ferretti GD, Daude N, Bertram L, Nogueira KO, Silva JL, Westaway Det al et al (2016) Regulation of amyloid beta oligomer binding to neurons and neurotoxicity by the prion protein-mGluR5 complex. J Biol Chem 291:21945\u201321955. https:\/\/doi.org\/10.1074\/jbc.M116.738286","journal-title":"J Biol Chem"},{"key":"2235_CR5","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M117.789990","author":"E Bove-Fenderson","year":"2017","unstructured":"Bove-Fenderson E, Urano R, Straub JE, Harris DA (2017) Cellular prion protein targets amyloid-beta fibril ends via its C-terminal domain to prevent elongation. J Biol Chem. https:\/\/doi.org\/10.1074\/jbc.M117.789990","journal-title":"J Biol Chem"},{"key":"2235_CR6","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/379339a0","volume":"379","author":"S Brandner","year":"1996","unstructured":"Brandner S, Isenmann S, Raeber A, Fischer M, Sailer A, Kobayashi Y, Marino S, Weissmann C, Aguzzi A (1996) Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature 379:339\u2013343. https:\/\/doi.org\/10.1038\/379339a0","journal-title":"Nature"},{"key":"2235_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/bs.apha.2017.09.007","volume":"82","author":"AH Brody","year":"2018","unstructured":"Brody AH, Strittmatter SM (2018) Synaptotoxic signaling by amyloid beta oligomers in alzheimer\u2019s disease through prion protein and mGluR5. Adv Pharmacol 82:293\u2013323. https:\/\/doi.org\/10.1016\/bs.apha.2017.09.007","journal-title":"Adv Pharmacol"},{"key":"2235_CR8","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s00213-004-1827-5","volume":"175","author":"UC Campbell","year":"2004","unstructured":"Campbell UC, Lalwani K, Hernandez L, Kinney GG, Conn PJ, Bristow LJ (2004) The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats. Psychopharmacology 175:310\u2013318. https:\/\/doi.org\/10.1007\/s00213-004-1827-5","journal-title":"Psychopharmacology"},{"key":"2235_CR9","doi-asserted-by":"publisher","unstructured":"Carroll JA, Race B, Williams K, Striebel J, Chesebro B (2018) Microglia are critical in host defense against prion disease. J Virol. https:\/\/doi.org\/10.1128\/JVI.00549-18","DOI":"10.1128\/JVI.00549-18"},{"key":"2235_CR10","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1146\/annurev.neuro.24.1.519","volume":"24","author":"J Collinge","year":"2001","unstructured":"Collinge J (2001) Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci 24:519\u2013550","journal-title":"Annu Rev Neurosci"},{"key":"2235_CR11","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00401-019-02114-9","volume":"139","author":"GT Corbett","year":"2020","unstructured":"Corbett GT, Wang Z, Hong W, Colom-Cadena M, Rose J, Liao M, Asfaw A, Hall TC, Ding L, DeSousa A al (2020) PrP is a central player in toxicity mediated by soluble aggregates of neurodegeneration-causing proteins. Acta Neuropathol 139:503\u2013526. https:\/\/doi.org\/10.1007\/s00401-019-02114-9","journal-title":"Acta Neuropathol"},{"key":"2235_CR12","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/brain\/awt375","volume":"137","author":"F Dohler","year":"2014","unstructured":"Dohler F, Sepulveda-Falla D, Krasemann S, Altmeppen H, Schluter H, Hildebrand D, Zerr I, Matschke J, Glatzel M (2014) High molecular mass assemblies of amyloid-beta oligomers bind prion protein in patients with Alzheimer\u2019s disease. Brain 137:873\u2013886","journal-title":"Brain"},{"key":"2235_CR13","doi-asserted-by":"publisher","first-page":"e1005623","DOI":"10.1371\/journal.ppat.1005623","volume":"12","author":"C Fang","year":"2016","unstructured":"Fang C, Imberdis T, Garza MC, Wille H, Harris DA (2016) A neuronal culture system to detect prion synaptotoxicity. PLoS Pathog 12:e1005623. https:\/\/doi.org\/10.1371\/journal.ppat.1005623","journal-title":"PLoS Pathog"},{"key":"2235_CR14","doi-asserted-by":"publisher","first-page":"e1007283","DOI":"10.1371\/journal.ppat.1007283","volume":"14","author":"C Fang","year":"2018","unstructured":"Fang C, Wu B, Le NTT, Imberdis T, Mercer RCC, Harris DA (2018) Prions activate a p38 MAPK synaptotoxic signaling pathway. PLoS Pathog 14:e1007283. https:\/\/doi.org\/10.1371\/journal.ppat.1007283","journal-title":"PLoS Pathog"},{"key":"2235_CR15","doi-asserted-by":"publisher","unstructured":"Ferreira DG, Temido-Ferreira M, Miranda HV, Batalha VL, Coelho JE, Szego EM, Marques-Morgado I, Vaz SH, Rhee JS, Schmitz M et al (2017) alpha-synuclein interacts with PrPC to induce cognitive impairment through mGluR5 and NMDAR2B. Nat Neurosci 20:1569\u20131579. https:\/\/doi.org\/10.1038\/nn.4648","DOI":"10.1038\/nn.4648"},{"key":"2235_CR16","doi-asserted-by":"publisher","first-page":"5863","DOI":"10.1093\/emboj\/20.21.5863","volume":"20","author":"S Gauczynski","year":"2001","unstructured":"Gauczynski S, Peyrin JM, Haik S, Leucht C, Hundt C, Rieger R, Krasemann S, Deslys JP, Dormont D, Lasmezas CIet al et al (2001) The 37-kDa\/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion protein. Embo J 20:5863\u20135875","journal-title":"Embo J"},{"key":"2235_CR17","doi-asserted-by":"publisher","unstructured":"Gomes LA, Hipp SA, Rijal Upadhaya A, Balakrishnan K, Ospitalieri S, Koper MJ, Largo-Barrientos P, Uytterhoeven V, Reichwald J, Rabe S et al (2019) Abeta-induced acceleration of Alzheimer-related tau-pathology spreading and its association with prion protein. Acta Neuropathol. https:\/\/doi.org\/10.1007\/s00401-019-02053-5","DOI":"10.1007\/s00401-019-02053-5"},{"key":"2235_CR18","doi-asserted-by":"publisher","unstructured":"Goniotaki D, Lakkaraju AKK, Shrivastava AN, Bakirci P, Sorce S, Senatore A, Marpakwar R, Hornemann S, Gasparini F, Triller A et al (2017) Inhibition of group-I metabotropic glutamate receptors protects against prion toxicity. PLoS Pathog 13:e1006733. https:\/\/doi.org\/10.1371\/journal.ppat.1006733","DOI":"10.1371\/journal.ppat.1006733"},{"key":"2235_CR19","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/brain\/awv356","volume":"139","author":"LT Haas","year":"2016","unstructured":"Haas LT, Salazar SV, Kostylev MA, Um JW, Kaufman AC, Strittmatter SM (2016) Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signalling in Alzheimer\u2019s disease. Brain 139:526\u2013546. https:\/\/doi.org\/10.1093\/brain\/awv356","journal-title":"Brain"},{"key":"2235_CR20","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.celrep.2017.06.023","volume":"20","author":"LT Haas","year":"2017","unstructured":"Haas LT, Salazar SV, Smith LM, Zhao HR, Cox TO, Herber CS, Degnan AP, Balakrishnan A, Macor JE, Albright CF al (2017) Silent allosteric modulation of mGluR5 maintains glutamate signaling while rescuing Alzheimer\u2019s mouse phenotypes. Cell Rep 20:76\u201388. https:\/\/doi.org\/10.1016\/j.celrep.2017.06.023","journal-title":"Cell Rep"},{"key":"2235_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1756-6606-7-40","volume":"7","author":"A Hamilton","year":"2014","unstructured":"Hamilton A, Esseltine JL, DeVries RA, Cregan SP, Ferguson SS (2014) Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer\u2019s disease. Mol Brain 7:40. https:\/\/doi.org\/10.1186\/1756-6606-7-40","journal-title":"Mol Brain"},{"key":"2235_CR22","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/j.celrep.2016.04.077","volume":"15","author":"A Hamilton","year":"2016","unstructured":"Hamilton A, Vasefi M, Vander Tuin C, McQuaid RJ, Anisman H, Ferguson SS (2016) Chronic pharmacological mGluR5 Inhibition prevents cognitive impairment and reduces pathogenesis in an Alzheimer disease mouse model. Cell Rep 15:1859\u20131865. https:\/\/doi.org\/10.1016\/j.celrep.2016.04.077","journal-title":"Cell Rep"},{"key":"2235_CR23","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1093\/brain\/awg125","volume":"126","author":"AF Hill","year":"2003","unstructured":"Hill AF, Joiner S, Wadsworth JD, Sidle KC, Bell JE, Budka H, Ironside JW, Collinge J (2003) Molecular classification of sporadic Creutzfeldt-Jakob disease. Brain 126:1333\u20131346","journal-title":"Brain"},{"key":"2235_CR24","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1038\/ncomms4374","volume":"5","author":"NW Hu","year":"2014","unstructured":"Hu NW, Nicoll AJ, Zhang D, Mably AJ, O\u2019Malley T, Purro SA, Terry C, Collinge J, Walsh DM, Rowan MJ (2014) mGlu5 receptors and cellular prion protein mediate amyloid-beta-facilitated synaptic long-term depression in vivo. Nat Commun 5:3374. https:\/\/doi.org\/10.1038\/ncomms4374","journal-title":"Nat Commun"},{"key":"2235_CR25","doi-asserted-by":"publisher","first-page":"844378","DOI":"10.3389\/fcell.2022.844378","volume":"10","author":"C Hu","year":"2022","unstructured":"Hu C, Chen C, Xia Y, Chen J, Yang W, Wang L, Chen DD, Wu YZ, Fan Q, Jia XX al (2022) Different aberrant changes of mGluR5 and its downstream signaling pathways in the Scrapie-Infected cell line and the brains of Scrapie-Infected experimental rodents. Front Cell Dev Biol 10:844378. https:\/\/doi.org\/10.3389\/fcell.2022.844378","journal-title":"Front Cell Dev Biol"},{"key":"2235_CR26","doi-asserted-by":"publisher","unstructured":"Hwang D, Lee IY, Yoo H, Gehlenborg N, Cho JH, Petritis B, Baxter D, Pitstick R, Young R, Spicer D et al (2009) A systems approach to prion disease. Mol Syst Biol 5:252. https:\/\/doi.org\/10.1038\/msb.2009.10","DOI":"10.1038\/msb.2009.10"},{"key":"2235_CR27","doi-asserted-by":"crossref","unstructured":"Jen A, Parkyn CJ, Mootoosamy RC, Ford MJ, Warley A, Liu Q, Bu G, Baskakov IV, Moestrup S, McGuinness L, Emptage N (2010) Neuronal low-density lipoprotein receptor-related protein 1 binds and endocytoses prion fibrils via receptor cluster 4. J Cell Sci 123:246\u2013255","DOI":"10.1242\/jcs.058099"},{"key":"2235_CR28","doi-asserted-by":"publisher","first-page":"e13906","DOI":"10.1371\/journal.pone.0013906","volume":"5","author":"S Krasemann","year":"2010","unstructured":"Krasemann S, Neumann M, Geissen M, Bodemer W, Kaup FJ, Schulz-Schaeffer W, Morel N, Aguzzi A, Glatzel M (2010) Preclinical deposition of pathological prion protein in muscle of experimentally infected primates. PLoS ONE 5:e13906. https:\/\/doi.org\/10.1371\/journal.pone.0013906","journal-title":"PLoS ONE"},{"key":"2235_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00401-012-0944-1","volume":"124","author":"S Krasemann","year":"2012","unstructured":"Krasemann S, Neumann M, Luepke JP, Grashorn J, Wurr S, Stocking C, Glatzel M (2012) Persistent retroviral infection with MoMuLV influences neuropathological signature and phenotype of prion disease. Acta Neuropathol 124:111\u2013126. https:\/\/doi.org\/10.1007\/s00401-012-0944-1","journal-title":"Acta Neuropathol"},{"key":"2235_CR30","doi-asserted-by":"publisher","unstructured":"Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O\u2019Loughlin E, Xu Y, Fanek Z et al (2017) The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47:566\u2013581. https:\/\/doi.org\/10.1016\/j.immuni.2017.08.008","DOI":"10.1016\/j.immuni.2017.08.008"},{"key":"2235_CR31","doi-asserted-by":"publisher","first-page":"e14714","DOI":"10.15252\/emmm.202114714","volume":"13","author":"AKK Lakkaraju","year":"2021","unstructured":"Lakkaraju AKK, Frontzek K, Lemes E, Herrmann U, Losa M, Marpakwar R, Aguzzi A (2021) Loss of PIKfyve drives the spongiform degeneration in prion diseases. EMBO Mol Med 13:e14714. https:\/\/doi.org\/10.15252\/emmm.202114714","journal-title":"EMBO Mol Med"},{"key":"2235_CR32","doi-asserted-by":"publisher","first-page":"16857","DOI":"10.1523\/JNEUROSCI.1858-12.2012","volume":"32","author":"M Larson","year":"2012","unstructured":"Larson M, Sherman MA, Amar F, Nuvolone M, Schneider JA, Bennett DA, Aguzzi A, Lesne SE (2012) The Complex PrPc-Fyn couples human oligomeric A\u03b2 with pathological tau changes in Alzheimer's disease. J Neurosci 32:16857\u201316871. https:\/\/doi.org\/10.1523\/JNEUROSCI.1858-12.2012","journal-title":"J Neurosci"},{"key":"2235_CR33","doi-asserted-by":"crossref","unstructured":"Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457:1128\u20131132","DOI":"10.1038\/nature07761"},{"key":"2235_CR34","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1073\/pnas.0409079102","volume":"102","author":"G Legname","year":"2005","unstructured":"Legname G, Nguyen HO, Baskakov IV, Cohen FE, Dearmond SJ, Prusiner SB (2005) Strain-specified characteristics of mouse synthetic prions. Proc Natl Acad Sci USA 102:2168\u20132173","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2235_CR35","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/sj.embor.embor768","volume":"4","author":"C Leucht","year":"2003","unstructured":"Leucht C, Simoneau S, Rey C, Vana K, Rieger R, Lasmezas CI, Weiss S (2003) The 37\u00a0kDa\/67\u00a0kDa laminin receptor is required for PrP(Sc) propagation in scrapie-infected neuronal cells. EMBO Rep 4:290\u2013295. https:\/\/doi.org\/10.1038\/sj.embor.embor768","journal-title":"EMBO Rep"},{"key":"2235_CR36","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1124\/jpet.111.185660","volume":"339","author":"L Lindemann","year":"2011","unstructured":"Lindemann L, Jaeschke G, Michalon A, Vieira E, Honer M, Spooren W, Porter R, Hartung T, Kolczewski S, Buttelmann Bet al et al (2011) CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor. J Pharmacol Exp Ther 339:474\u2013486. https:\/\/doi.org\/10.1124\/jpet.111.185660","journal-title":"J Pharmacol Exp Ther"},{"key":"2235_CR37","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1124\/jpet.114.222463","volume":"353","author":"L Lindemann","year":"2015","unstructured":"Lindemann L, Porter RH, Scharf SH, Kuennecke B, Bruns A, von Kienlin M, Harrison AC, Paehler A, Funk C, Gloge Aet al et al (2015) Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression. J Pharmacol Exp Ther 353:213\u2013233. https:\/\/doi.org\/10.1124\/jpet.114.222463","journal-title":"J Pharmacol Exp Ther"},{"key":"2235_CR38","doi-asserted-by":"publisher","first-page":"5196","DOI":"10.1523\/JNEUROSCI.17-13-05196.1997","volume":"17","author":"YM Lu","year":"1997","unstructured":"Lu YM, Jia Z, Janus C, Henderson JT, Gerlai R, Wojtowicz JM, Roder JC (1997) Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J Neurosci 17:5196\u20135205","journal-title":"J Neurosci"},{"key":"2235_CR39","doi-asserted-by":"publisher","first-page":"eads6967","DOI":"10.1126\/sciadv.ads6967","volume":"11","author":"AI Luppi","year":"2025","unstructured":"Luppi AI, Liu ZQ, Hansen JY, Cofre R, Niu M, Kuzmin E, Froudist-Walsh S, Palomero-Gallagher N, Misic B (2025) Benchmarking macaque brain gene expression for horizontal and vertical translation. Sci Adv 11:eads6967. https:\/\/doi.org\/10.1126\/sciadv.ads6967","journal-title":"Sci Adv"},{"key":"2235_CR40","doi-asserted-by":"publisher","first-page":"104783","DOI":"10.1016\/j.nbd.2020.104783","volume":"137","author":"N Makarava","year":"2020","unstructured":"Makarava N, Chang JC, Molesworth K, Baskakov IV (2020) Region-specific glial homeostatic signature in prion diseases is replaced by a uniform neuroinflammation signature, common for brain regions and prion strains with different cell tropism. Neurobiol Dis 137:104783. https:\/\/doi.org\/10.1016\/j.nbd.2020.104783","journal-title":"Neurobiol Dis"},{"key":"2235_CR41","doi-asserted-by":"publisher","DOI":"10.1172\/JCI181169","author":"N Makarava","year":"2024","unstructured":"Makarava N, Safadi T, Bocharova O, Mychko O, Pandit NP, Molesworth K, Baiardi S, Zhang L, Parchi P, Baskakov IV (2024) Reactive microglia partially envelop viable neurons in prion diseases. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI181169","journal-title":"J ClinInvest"},{"key":"2235_CR42","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12974-025-03542-z","volume":"22","author":"N Makarava","year":"2025","unstructured":"Makarava N, Safadi T, Bocharova O, Mychko O, Pandit NP, Molesworth K, Eyo UB, Baskakov IV (2025) Knockout of P2Y12 receptor facilitates neuronal envelopment by reactive microglia and accelerates prion disease. J Neuroinflamm 22:210. https:\/\/doi.org\/10.1186\/s12974-025-03542-z","journal-title":"J Neuroinflammation"},{"key":"2235_CR43","doi-asserted-by":"publisher","first-page":"e29811","DOI":"10.1002\/jmv.29811","volume":"96","author":"J Matschke","year":"2024","unstructured":"Matschke J, Hartmann K, Pfefferle S, Wang Y, Valdes PA, Thies E, Schweizer M, Lutgehetmann M, Schmiedel S, Bernreuther Cet al et al (2024) Inefficient tissue immune response against MPXV in an immunocompromised Mpox patient. J Med Virol 96:e29811. https:\/\/doi.org\/10.1002\/jmv.29811","journal-title":"J Med Virol"},{"key":"2235_CR44","doi-asserted-by":"publisher","first-page":"10615","DOI":"10.1093\/nar\/gkaa616","volume":"48","author":"EV Minikel","year":"2020","unstructured":"Minikel EV, Zhao HT, Le J, O\u2019Moore J, Pitstick R, Graffam S, Carlson GA, Kavanaugh MP, Kriz J, Kim JB al (2020) Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints. Nucleic Acids Res 48:10615\u201310631. https:\/\/doi.org\/10.1093\/nar\/gkaa616","journal-title":"Nucleic Acids Res"},{"key":"2235_CR45","doi-asserted-by":"publisher","unstructured":"Mortberg MA, Gentile JE, Nadaf NM, Vanderburg C, Simmons S, Dubinsky D, Slamin A, Maldonado S, Petersen CL, Jones N et al (2023) A single-cell map of antisense oligonucleotide activity in the brain. Nucleic Acids Res. https:\/\/doi.org\/10.1093\/nar\/gkad371","DOI":"10.1093\/nar\/gkad371"},{"key":"2235_CR46","doi-asserted-by":"publisher","first-page":"105834","DOI":"10.1016\/j.nbd.2022.105834","volume":"172","author":"D Ojeda-Juarez","year":"2022","unstructured":"Ojeda-Juarez D, Lawrence JA, Soldau K, Pizzo DP, Wheeler E, Aguilar-Calvo P, Khuu H, Chen J, Malik A, Funk G al (2022) Prions induce an early arc response and a subsequent reduction in mGluR5 in the hippocampus. Neurobiol Dis 172:105834. https:\/\/doi.org\/10.1016\/j.nbd.2022.105834","journal-title":"Neurobiol Dis"},{"key":"2235_CR47","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/sj.embor.embor731embor731","volume":"4","author":"M Prinz","year":"2003","unstructured":"Prinz M, Heikenwalder M, Schwarz P, Takeda K, Akira S, Aguzzi A (2003) Prion pathogenesis in the absence of toll-like receptor signalling. EMBO Rep 4:195\u2013199. https:\/\/doi.org\/10.1038\/sj.embor.embor731embor731","journal-title":"EMBO Rep"},{"key":"2235_CR48","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1126\/science.6801762","volume":"216","author":"SB Prusiner","year":"1982","unstructured":"Prusiner SB (1982) Novel proteinaceous infectious particles cause scrapie. Science 216:136\u2013144","journal-title":"Science"},{"key":"2235_CR49","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1038\/emboj.2008.122","volume":"27","author":"AS Rambold","year":"2008","unstructured":"Rambold AS, Muller V, Ron U, Ben-Tal N, Winklhofer KF, Tatzelt J (2008) Stress-protective signalling of prion protein is corrupted by scrapie prions. Embo J 27:1974\u20131984. https:\/\/doi.org\/10.1038\/emboj.2008.122","journal-title":"Embo J"},{"key":"2235_CR50","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1038\/emboj.2011.86","volume":"30","author":"UK Resenberger","year":"2011","unstructured":"Resenberger UK, Harmeier A, Woerner AC, Goodman JL, Muller V, Krishnan R, Vabulas RM, Kretzschmar HA, Lindquist S, Hartl FUet al et al (2011) The cellular prion protein mediates neurotoxic signalling of beta-sheet-rich conformers independent of prion replication. EMBO J 30:2057\u20132070","journal-title":"EMBO J"},{"key":"2235_CR51","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1186\/s12859-017-1934-z","volume":"18","author":"CT Rueden","year":"2017","unstructured":"Rueden CT, Schindelin J, Hiner MC, DeZonia BE, Walter AE, Arena ET, Eliceiri KW (2017) ImageJ2: imageJ for the next generation of scientific image data. BMC Bioinformatics 18:529. https:\/\/doi.org\/10.1186\/s12859-017-1934-z","journal-title":"BMC Bioinformatics"},{"key":"2235_CR52","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nature09768","volume":"470","author":"MK Sandberg","year":"2011","unstructured":"Sandberg MK, Al-Doujaily H, Sharps B, Clarke AR, Collinge J (2011) Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature 470:540\u2013542","journal-title":"Nature"},{"key":"2235_CR53","doi-asserted-by":"publisher","first-page":"119240","DOI":"10.1016\/j.bbamcr.2022.119240","volume":"1869","author":"M Shafiq","year":"2022","unstructured":"Shafiq M, Da Vela S, Amin L, Younas N, Harris DA, Zerr I, Altmeppen HC, Svergun D, Glatzel M (2022) The prion protein and its ligands: insights into structure-function relationships. Biochim Biophys Acta Mol Cell Res 1869:119240. https:\/\/doi.org\/10.1016\/j.bbamcr.2022.119240","journal-title":"Biochim Et Biophys Acta Mol Cell Res"},{"key":"2235_CR54","doi-asserted-by":"publisher","unstructured":"Spurrier J, Nicholson L, Fang XT, Stoner AJ, Toyonaga T, Holden D, Siegert TR, Laird W, Allnutt MA, Chiasseu M et al (2022) Reversal of synapse loss in Alzheimer mouse models by targeting mGluR5 to prevent synaptic tagging by C1Q. Sci Transl Med 14:eabi8593 https:\/\/doi.org\/10.1126\/scitranslmed.abi8593","DOI":"10.1126\/scitranslmed.abi8593"},{"key":"2235_CR55","doi-asserted-by":"publisher","unstructured":"Stoner A, Fu L, Nicholson L, Zheng C, Toyonaga T, Spurrier J, Laird W, Cai Z, Strittmatter SM (2023) Neuronal transcriptome, tau and synapse loss in Alzheimer\u2019s knock-in mice require prion protein. Alzheimers Res Ther 15:201. https:\/\/doi.org\/10.1186\/s13195-023-01345-z","DOI":"10.1186\/s13195-023-01345-z"},{"key":"2235_CR56","doi-asserted-by":"publisher","first-page":"718953","DOI":"10.3389\/fpsyt.2021.718953","volume":"12","author":"DC Stoppel","year":"2021","unstructured":"Stoppel DC, McCamphill PK, Senter RK, Heynen AJ, Bear MF (2021) mGluR5 negative modulators for fragile X: treatment resistance and persistence. Front Psychiatry 12:718953. https:\/\/doi.org\/10.3389\/fpsyt.2021.718953","journal-title":"Front Psychiatry"},{"key":"2235_CR57","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"D Szklarczyk","year":"2023","unstructured":"Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, Gable AL, Fang T, Doncheva NT, Pyysalo Set al et al (2023) The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res 51:D638\u2013D646. https:\/\/doi.org\/10.1093\/nar\/gkac1000","journal-title":"Nucleic Acids Res"},{"key":"2235_CR58","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.neuron.2013.06.036","volume":"79","author":"JW Um","year":"2013","unstructured":"Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, Takahashi H, Kerrisk ME, Vortmeyer A, Wisniewski T, Koleske AJ al (2013) Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer a\u03b2 oligomer bound to cellular prion protein. Neuron 79:887\u2013902 Doi S0896-6273(13)00552-7 [pii]. https:\/\/doi.org\/10.1016\/j.neuron.2013.06.036","journal-title":"Neuron"},{"key":"2235_CR59","doi-asserted-by":"crossref","unstructured":"Wickham H (2016) Data analysis. In: ggplot2: elegant graphics for data analysis, 2nd edn. Springer, Cham, pp 189\u2013201","DOI":"10.1007\/978-3-319-24277-4_9"},{"key":"2235_CR60","doi-asserted-by":"publisher","first-page":"13028","DOI":"10.1523\/JNEUROSCI.2600-08.2008","volume":"28","author":"LS Wijetunge","year":"2008","unstructured":"Wijetunge LS, Till SM, Gillingwater TH, Ingham CA, Kind PC (2008) mGluR5 regulates glutamate-dependent development of the mouse somatosensory cortex. J Neurosci 28:13028\u201313037. https:\/\/doi.org\/10.1523\/JNEUROSCI.2600-08.2008","journal-title":"J Neurosci"},{"key":"2235_CR61","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1001\/jamaneurol.2024.4447","volume":"82","author":"R Wurm","year":"2025","unstructured":"Wurm R, Klotz S, Erber A, Gruber F, Leitner S, Reichardt B, Stogmann E, Schernhammer E, Gelpi E, Cetin H (2025) Mood alterations in the prodromal phase of sporadic Creutzfeldt-Jakob disease. JAMA Neurol 82:185\u2013192. https:\/\/doi.org\/10.1001\/jamaneurol.2024.4447","journal-title":"JAMA Neurol"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-026-02235-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-026-02235-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-026-02235-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:17:32Z","timestamp":1781630252000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40478-026-02235-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2235"],"URL":"https:\/\/doi.org\/10.1186\/s40478-026-02235-9","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work is entirely novel and not under considered elsewhere. All authors have approved the final version of the manuscript and agree with its submission and publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SM.S. is founder, equity holder, director, and paid consultant of Allyx Therapeutics, which seeks to develop mGluR5 compounds for AD and holds a license for BMS-984923\/ALX-001. The other authors declare that there is no conflict of interest with regard to this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"83"}}